NIH F32 Grants — Individual Postdoctoral Fellowship

Recent F32 awards from NIH RePORTER

Examples of funded F32 projects across the last two fiscal years. The matching-award count comes from the full result set; funding totals, averages, rankings, and examples use the first 500 records returned by NIH RePORTER. Figures reflect a snapshot last refreshed on June 9, 2026.

Example F32 projects from the sample

• Leveraging machine learning and EMA data to identify factors that predict children's energy intake

  5F32HD116537-02
  Hanim Diktas · LSU PENNINGTON BIOMEDICAL RESEARCH CTR, LA · $79,348 · awarded Jun 1, 2026 · NIH

  PROJECT SUMMARY The collection of real time data through technology-based approaches, such as ecological momentary assessment (EMA), presents a rich source of information for understanding concurrent predictors of children’s eating behaviors. However, advanced statistical programming methods are needed to transition from real-time assessment to real-time…

• Understanding the relationship between sleep, motor learning, and motor development in early childhood

  5F32HD117609-02
  MELISSA HORGER · UNIVERSITY OF MASSACHUSETTS AMHERST, MA · $81,580 · awarded Jun 1, 2026 · NIH

  PROJECT SUMMARY Early childhood is a period of neuroplasticity and change across physiological, cognitive, and behavioral domains. Interactions among domains abound and cumulatively support future health outcomes. The present fellowship hones in on the relationship between sleep and motor development. Research with adults supports the impact of specific…

• Determining the Molecular Arrangement of GABABR-GIRK Signaling Cascades

  5F32DA063169-02
  Kevin Knight · UNIVERSITY OF FLORIDA, FL · $79,348 · awarded Jun 1, 2026 · NIH

  Project Summary/Abstract Drug addiction is marked by functional changes to once healthy cell signaling pathways. Drugs of abuse such as morphine, cannabinoids, cocaine, and gamma-hydroxybutyrate (GHB) disrupt inhibitory neurotransmission signaling through G protein-coupled inward rectifying potassium (GIRK) channels. In fact, while some substances like…

• Engineering RIG-I Activating Nanoparticles for Glioblastoma Immunotherapy

  5F32CA288044-03
  Alexander Kwiatkowski · VANDERBILT UNIVERSITY, TN · $79,348 · awarded May 27, 2026 · NIH

  Glioblastoma (GBM) is a form of brain cancer with no cure and a five-year survival rate below 10%. Immunotherapies such as immune checkpoint blockade (ICB) have shown great promise in other solid tumors but have demonstrated no clinical benefits for GBM patients. In part due to a highly immunosuppressive tumor microenvironment that inhibits T cell…

• Factors associated with changes in glycemic control and type 2 diabetes self-management among Hispanic adults following a digital storytelling intervention

  5F32DK135200-03
  Abby Lohr · MAYO CLINIC ROCHESTER, MN · $82,348 · awarded May 25, 2026 · NIH

  PROJECT SUMMARY/ABSTRACT Hispanic Americans experience a high burden of type 2 diabetes (T2D) and suboptimal diabetes-related outcomes, including glycemic control, medication adherence, physical activity, dietary quality, and glucose self-monitoring. Interventions that measurably improve these outcomes in culturally relevant ways are needed. Digital…

• Development of a Three-Component Iron-Catalyzed Difluoromethylation Reaction

  1F32GM165088-01
  Lupita Aguirre · UNIVERSITY OF CALIFORNIA LOS ANGELES, CA · $75,880 · awarded May 20, 2026 · NIH

  Project Summary/Abstract The incorporation of difluoromethyl (–CF2H) group has become a leading strategy in pharmaceutical development to enhance drug performance due to –CF2H’s unique and profound bioisosteric activity for hydroxyls, amines, and thiols as a result of its hydrogen bond ability. Presently, transition metal-mediated approaches for the direct…

• Dissecting Spatial and Molecular Dynamics of Immune-Vascular Crosstalk to Overcome ImmuneBarriers in iPSC-Based Therapies

  1F32HL184543-01
  Umji Lee · BOSTON CHILDREN'S HOSPITAL, MA · $84,580 · awarded May 18, 2026 · NIH

  PROJECT SUMMARY/ABSTRACT Induced pluripotent stem cells (iPSCs) offer a promising platform for regenerative medicine, with their ability to self-renew indefinitely and differentiate into vascular cells. However, their clinical translation in vascular diseases is limited by major challenges: the impracticality of autologous therapy, immune rejection in…

• Using latent cause modeling and neurofeedback to understand fear relapse and its relationship to anxiety

  5F32MH140486-02
  Augustin Hennings · PRINCETON UNIVERSITY, NJ · $81,580 · awarded May 13, 2026 · NIH

  PROJECT SUMMARY/ABSTRACT Exposure therapy is the most effective evidence-based treatment for a variety of anxiety disorders, but relapse is common. Failures of exposure therapy can be explained in part by laboratory studies using aversive conditioning and extinction, where the extinction phase can be viewed as a model of exposure therapy. These studies show…

• Anaplasma phagocytophilum exploitation of regulated exocytosis.

  5F32AI183749-03
  Travis Chiarelli · VIRGINIA COMMONWEALTH UNIVERSITY, VA · $79,348 · awarded May 7, 2026 · NIH

  SUMMARY Regulated exocytosis is a conserved eukaryotic process that is essential for numerous cellular functions, making it a prime target for exploitation by both infectious and non-infectious diseases. Indeed, various malignancies, viruses, bacteria, and protozoa commandeer this pathway to promote disease progression. Numerous studies have interrogated…

• The Role of SMARCAL1 Depletion on Increased Immunogenicity in ALT+ Gliomas

  5F32CA298007-02
  Elise Erman · DUKE UNIVERSITY, NC · $79,348 · awarded May 7, 2026 · NIH

  PROJECT SUMMARY/ABSTRACT. Approximately 10 to 15% of all cancers utilize the alternative lengthening of telomeres (ALT) mechanism to maintain telomere length and achieve replicative immortality. ALT occurs frequently in high-grade gliomas (HGGs), including IDH-mutant astrocytomas, pediatric HGGs with H3G34R mutations, and a subset of adult primary GBMs. The…

• Influence of social environment on the neural mechanisms of sickness

  1F32MH140490-01A1
  Danielle Germundson-Hermanson · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH, UT · $79,348 · awarded May 7, 2026 · NIH

  PROJECT SUMMARY During sickness, the immune system and central nervous system coordinate to generate physical and behavioral changes, such as lethargy, anorexia, anhedonia, and social withdrawal, that can vary significantly in severity between individuals. While these symptoms help aid in sickness recovery, severe responses can be harmful and possibly…

• A Comparative Analysis of OPC and Microglia Phagocytosis and its Relevance to Neurodegenerative Disease

  5F32NS134683-03
  Rebecca Beiter · UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA · $73,769 · awarded May 5, 2026 · NIH

  PROJECT SUMMARY/ABSTRACT The overarching goal of this proposal is to gain a deeper understanding of oligodendrocyte progenitor cell (OPC) phagocytosis and determine how it compares to the phagocytic ability of microglia and its relevance for neurological disease. Oligodendrocyte progenitor cells (OPCs) are a pool of progenitors found in the adult brain that…

Compare nearby NIH grant mechanisms

Searchers often land on F32 while deciding between adjacent NIH activity codes. Compare scope, NIH staff involvement, budget scale, and applicant stage before choosing a funding opportunity.